Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6VY3P)

Drug Name
NSC-94258 Drug Info
Synonyms
7-Hydroxyflavone; 6665-86-7; 7-Hydroxy-2-phenyl-4H-chromen-4-one; Flavone, 7-hydroxy-; 7-Hydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 7-hydroxy-2-phenyl-; 7-hydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-; 7-Hydroxy-2-phenyl-chromen-4-one; NSC 94258; UNII-ZE72458E4L; EINECS 229-705-3; NSC-94258; MLS002695239; CHEBI:2268; CHEMBL276915; MQGPSCMMNJKMHQ-UHFFFAOYSA-N; ZE72458E4L; NSC94258; MFCD00006835; 7-Hydroxy-2-phenyl-4H-1-benzopyran-4-one; H-5100; SR-01000359106; 7-Hydroxyflavone, 11; 7-Hydroxy-flavone,
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5281894
ChEBI ID
CHEBI:2268
CAS Number
CAS 6665-86-7
TTD Drug ID
DM6VY3P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Aromatase (CYP19A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Anastrozole DMNP60F Breast cancer 2C60-2C65 Approved [10]
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [11]
Exemestane DM9HPW3 Hormonally-responsive breast cancer 2C60-2C65 Approved [11]
Aminoglutethimide DMWFHMZ Cushing disease 5A70 Approved [12]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [13]
Testolactone DMVY4GN Breast cancer 2C60-2C65 Approved [14]
LIAROZOLE DM4OYXE Dermatological disease DA24.Y Phase 2/3 [3]
Coumate DMVKW0N Breast cancer 2C60-2C65 Phase 2 [15]
BGS-649 DMO4MNQ Endometriosis GA10 Phase 2 [16]
NARINGENIN DMHAZLM N. A. N. A. Phase 1 [3]
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [29]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [30]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [31]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [32]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [31]
Methotrexate DM2TEOL Anterior urethra cancer Approved [33]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [34]
Bifonazole DM3KN7V Fungal infection 1F29-1F2F Approved [35]
Quercetin DM3NC4M Obesity 5B81 Approved [36]
Fluoxetine DM3PD2C Bipolar depression Approved [31]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Targeting Aldose reductase (AKR1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epalrestat DM5OGK0 Diabetic neuropathy 8C0Z Approved [17]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [18]
Fidarestat DMZL1I8 Diabetic complication 5A2Y Phase 3 [19]
Ranirestat DMD5QRS Diabetic neuropathy 8C0Z Phase 3 [20]
CONTIGOSIDE B DMX9V8K Thrombosis DB61-GB90 Phase 2/3 [21]
BNV-222 DMYFQJL Diabetic neuropathy 8C0Z Phase 2/3 [20]
BNV-222 DMYFQJL Diabetic neuropathy 8C0Z Phase 2/3 [22]
LIDORESTAT DMA0RI9 Diabetic complication 5A2Y Phase 2 [23]
QR-333 DMKVIWM Diabetic neuropathy 8C0Z Phase 2 [24]
ADMVA DM819CO Diabetic complication 5A2Y Phase 2 [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NARINGENIN DMHAZLM N. A. N. A. Phase 1 [1]
Nicotinamide-Adenine-Dinucleotide DM9LRKB N. A. N. A. Investigative [25]
2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M Discovery agent N.A. Investigative [25]
APIGENIN DMI3491 Discovery agent N.A. Investigative [1]
KAEMPFEROL DMHEMUB Discovery agent N.A. Investigative [1]
4-ANDROSTENE-3-17-DIONE DMSE8NU Discovery agent N.A. Investigative [25]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol DMH8WA2 Discovery agent N.A. Investigative [26]
7-(3-Hydroxy-phenyl)-naphthalen-2-ol DM2I91C Discovery agent N.A. Investigative [27]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol DM7ERYJ Discovery agent N.A. Investigative [28]
6-(4-Hydroxy-phenyl)-naphthalen-1-ol DM2V9XI Discovery agent N.A. Investigative [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [37]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [38]
Diazepam DM08E9O Alcohol withdrawal Approved [39]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [40]
Desogestrel DM27U4Y Contraception QA21 Approved [40]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [38]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [38]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [4]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [43]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [44]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [45]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [46]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [47]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [48]
Ethacrynic acid DM60QMR Edema MG29 Approved [49]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [50]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [51]
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [53]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [53]
Etoricoxib DM6A4NW Rheumatoid arthritis FA20 Approved [53]
Capsaicin DMGMF6V Back pain ME84.Z Approved [54]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [7]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [55]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [56]
Zileuton DMVRIC2 Allergic asthma CA23.0 Approved [57]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [58]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [60]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [61]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [62]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [63]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [64]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [64]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [65]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [66]
Capsaicin DMGMF6V Back pain ME84.Z Approved [67]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [68]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [61]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [69]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [64]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [63]
Capsaicin DMGMF6V Back pain ME84.Z Approved [54]
Zafirlukast DMHNQOG Asthma CA23 Approved [70]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [64]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [71]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [63]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [64]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [61]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [72]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [63]
Chloramphenicol DMFXEWT Bacterial infection 1A00-1C4Z Approved [73]
Capsaicin DMGMF6V Back pain ME84.Z Approved [54]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [64]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [55]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [64]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [72]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [74]
2-deoxyglucose DMIAHVU Solid tumour/cancer 2A00-2F9Z Approved [75]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [76]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [77]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [78]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [79]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [78]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [42]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [80]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [81]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aldose reductase (AKR1B1) TTFBNVI ALDR_HUMAN Inhibitor [2]
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [3]
Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) TTIWB6L DHB1_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [4]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Gene/Protein Processing [5]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [6]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Gene/Protein Processing [6]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Gene/Protein Processing [7]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Gene/Protein Processing [7]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [6]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Gene/Protein Processing [8]
UDP-glucuronosyltransferase 2B15 OTABTFU2 UDB15_HUMAN Regulation of Drug Effects [9]

References

1 Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
2 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93.
3 Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
4 AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
5 Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol Sci. 2004 Nov;82(1):70-9.
6 Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol. 2010 Dec 20;23(12):1921-35.
7 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
8 The inhibitory effects of flavonoids and antiestrogens on the Glut1 glucose transporter in human erythrocytes. Chem Biol Interact. 2003 Dec 15;146(3):225-35. doi: 10.1016/j.cbi.2003.06.001.
9 Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab Dispos. 1994 Sep-Oct;22(5):799-805.
10 Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
11 Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
12 Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
13 Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
14 Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
15 Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
16 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
17 Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
18 Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
19 Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
21 Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
22 ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
23 Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
24 A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
25 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
26 Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
27 Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
28 New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
29 Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
30 Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
31 Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
32 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
33 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
34 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
35 Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
36 Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
37 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
38 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
39 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
40 Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
41 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
42 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
43 Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
44 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
45 Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
46 Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
47 Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
48 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
49 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
50 Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
51 The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
52 Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
53 In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
54 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
55 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
56 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
57 Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
58 Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
59 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
60 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
61 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
62 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
63 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
64 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
65 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
66 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
67 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
68 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
69 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
70 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
71 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
72 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
73 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
74 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
75 Insulin regulation of hexose transport in mouse 3T3-L1 cells expressing the human HepG2 glucose transporter. J Biol Chem. 1990 Nov 25;265(33):20106-16.
76 Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun. 2001 Jan 26;280(3):664-74. doi: 10.1006/bbrc.2000.4216.
77 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
78 Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. Toxicol Lett. 2009 Jan 30;184(2):81-4. doi: 10.1016/j.toxlet.2008.10.017. Epub 2008 Oct 28.
79 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
80 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
81 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.